

Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

KHOS-240S

RRID:CVCL_2544

Type: Cell Line

Proper Citation

RRID:CVCL_2544

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2544

Proper Citation: RRID:CVCL_2544

Description: Cell line KHOS-240S is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Osteosarcoma

Defining Citation: [PMID:62397](#), [PMID:2233717](#), [PMID:2978869](#), [PMID:20215515](#), [PMID:26351324](#), [PMID:28196595](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KHOS-240S

Synonyms: KHOS240S, 240S

Cross References: BTO:BTO_0003923, CLO:CLO_0007098, EFO:EFO_0002219, CLDB:cl3028, ArrayExpress:E-MTAB-38, ATCC:CRL-1545, cancercellines:CVCL_2544, CCTCC:GDC0254, CLS:300433, Cosmic:1074392, ECACC:86112810, GEO:GSM186426, GEO:GSM186427, GEO:GSM827381, GEO:GSM1676358, GEO:GSM1701688, IGRhCellID:KHOS240S, LINCS_LDP:LCL-1426, Progenetix:CVCL_2544, Wikidata:Q54899909

ID: CVCL_2544

Hierarchy: cvcl_2546

Record Creation Time: 20220427T220702+0000

Record Last Update: 20260905T180937+0000

Ratings and Alerts

No rating or validation information has been found for KHOS-240S.

No alerts have been found for KHOS-240S.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Sotiriou A, et al. (2026) BAF complex-independent gene activation by SS18::SSX. bioRxiv : the preprint server for biology.

Guo L, et al. (2026) The ITGB2-COPS3-SOX2 Axis and SOX2 Liquid-Liquid Phase Separation: Dual Mechanisms Governing Osteosarcoma Stemness. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(29), e20913.

Ren Z, et al. (2026) MAT2A enhances PARN transcription via SRF to accelerate glycolysis and drive malignant progression in osteosarcoma. Communications biology, 9(1), 241.

Hasegawa N, et al. (2025) DNA demethylating agents suppress preclinical models of synovial sarcoma. The Journal of clinical investigation, 135(13).

Benabdallah NS, et al. (2023) Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability. Nature structural & molecular biology, 30(11), 1640.

Yang Z, et al. (2022) ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner. EBioMedicine, 80, 104019.

Heidler CL, et al. (2020) Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib. International journal of cancer, 147(4), 1059.